Risk Factors for DXA Screening in Postmenopausal Women Under 65 Years
Postmenopausal women younger than 65 years should undergo DXA screening if they have clinical risk factors for osteoporosis, using a 2-step approach: first assess fracture risk with a clinical tool, then proceed to DXA if risk is elevated. 1
Specific Risk Factors That Warrant DXA Screening
The 2025 USPSTF guidelines 1 and 2020 AACE guidelines 2 identify the following risk factors that qualify postmenopausal women under 65 for DXA:
Major Risk Factors:
- Low body weight (<57.6 kg or 127 lbs) 2
- Prior fragility fracture (any fracture without major trauma after age 50, excluding fingers, toes, skull) 2
- Long-term glucocorticoid therapy (≥5 mg prednisone daily for ≥3 months) 2, 3
- Radiographic osteopenia on imaging 2
Additional Clinical Risk Factors:
- Current cigarette smoking 2
- Excessive alcohol intake (>3 drinks daily) 2
- Early menopause 2
- Family history of hip or spine fractures 2
- Secondary causes of osteoporosis (type 1 diabetes, hyperthyroidism, hypogonadism, chronic malnutrition/malabsorption, chronic liver disease) 2
- Rheumatoid arthritis 2
Recommended Screening Approach
The USPSTF suggests a 2-step process for women under 65: 1
- First: Use a formal clinical risk assessment tool (such as FRAX, Osteoporosis Self-Assessment Tool, or similar validated instruments) to identify those at increased fracture risk
- Second: Proceed to DXA scanning only if the risk assessment indicates elevated risk
This approach is more efficient than universal screening and targets those most likely to benefit from intervention. The guidelines emphasize that DXA can be performed with or without concurrent fracture risk assessment, but the 2-step approach is preferred for younger postmenopausal women 1.
Important Clinical Considerations
Common pitfall: Do not screen women under 65 without any risk factors—this leads to unnecessary testing and potential overtreatment 3. The evidence supports selective screening based on risk stratification rather than age-based universal screening in this population.
Key distinction: While all women ≥65 years should be screened regardless of risk factors, younger postmenopausal women require the presence of at least one clinical risk factor to justify DXA 1, 2.
The strength of this recommendation is based on the 2025 USPSTF guidelines published in JAMA 1, which represent the most current and authoritative guidance, consistent with the 2020 AACE guidelines 2 and supported by multiple professional societies 3, 4.